Northland Securities reiterated their buy rating on shares of Evgen Pharma (LON:EVG) in a research report released on Tuesday, March 20th.
A number of other analysts have also recently issued reports on the company. Beaufort Securities reaffirmed a speculative buy rating on shares of Evgen Pharma in a research report on Friday, December 15th. Northland Capital Partners reissued a corporate rating on shares of Evgen Pharma in a report on Monday, March 5th.
Shares of EVG traded up GBX 0.25 ($0.00) during mid-day trading on Tuesday, reaching GBX 13 ($0.18). The company’s stock had a trading volume of 80,873 shares, compared to its average volume of 207,445. Evgen Pharma has a 1-year low of GBX 12.15 ($0.17) and a 1-year high of GBX 29.25 ($0.41).
COPYRIGHT VIOLATION WARNING: This article was first posted by Macon Daily and is owned by of Macon Daily. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://macondaily.com/2018/04/12/evgen-pharma-evg-given-buy-rating-at-northland-securities-updated-updated-updated.html.
About Evgen Pharma
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane.
Receive News & Ratings for Evgen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.